Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
- None.
- None.
Insights
The issuance of U.S. Patent No. 11,918,594 and the expected issuance of U.S. Patent No. 11,931,338 for Enveric Biosciences represent a strategic fortification of the company's intellectual property (IP) assets. The composition of matter patents are critical in the pharmaceutical industry, as they provide exclusive rights to the chemical makeup of new drug compounds, which is a more robust form of protection compared to method-of-use patents. This exclusivity can prevent competitors from developing or selling similar compounds for the duration of the patent, typically 20 years from the filing date.
The mention of non-disclosed drug candidates and six compounds tied to recent Non-Binding Term Sheets suggests a broadening of Enveric's potential market opportunities. This could attract licensing deals, partnerships and investment, as patented compounds can be more lucrative and appealing to both investors and pharmaceutical partners. Furthermore, these patents can significantly enhance the company's valuation and are likely to impact its stock positively in the short term due to the market's perception of strengthened proprietary protection and long-term revenue potential.
Enveric's expansion of their patent portfolio with novel psilocybin derivatives is indicative of the growing interest and potential within the psychopharmacological treatment market. Mental health disorders represent a significant and growing market, with a global antidepressant drug market size valued at billions and expected to grow steadily. The patenting of new chemical entities, especially in the psychedelics space, is a sign of Enveric's commitment to innovation and capturing market share in a niche but expanding segment.
Investors should note the strategic emphasis on the PsybraryTM collection, which could become a significant asset if the compounds show clinical efficacy. Enveric's focus on advancing its lead programs, EB-002 and EB-003, while also inviting drug development of its collection by others, suggests a dual-path strategy to revenue generation—developing in-house programs and licensing out other compounds. This approach can diversify risk and create multiple streams of potential income.
The patented compounds and the associated research into neuroplastogenic small-molecule therapeutics address a critical need in the treatment of depression, anxiety and addiction disorders. Current treatments for these conditions often have limitations such as side effects or incomplete efficacy, creating a demand for novel therapeutics. Enveric's focus on developing proprietary compounds could lead to breakthroughs in mental health treatment.
While the patents are a positive sign of innovation, the true value lies in the clinical success of these compounds. Investors should monitor the progress of Enveric's lead programs, as successful clinical trials can greatly enhance the compounds' value and the company's market position. The long-term impact of these patents will be contingent upon successful drug development, regulatory approval and market acceptance of the novel treatments.
Patents extend compositional protection to proprietary compounds
The newly issued patent and soon to be issued patent provide composition of matter claim coverage on numerous potential drug candidates not previously publicly disclosed by Enveric, as well as to six compounds subject to the three recently announced Non-Binding Term Sheets that Enveric entered into with an undisclosed biotechnology company.
“The new patent and soon-to-issue patent expand our patent portfolio and strengthen the opportunity presented to our current and future partners and licensees. They also highlight the breadth of the available patent coverage for other molecules available for licensing in the Company’s PsybraryTM collections of licensable portfolios,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “These developments further demonstrate and validate the value of opportunities presented by Enveric to potential licensees seeking to develop novel chemical entities into proprietary, patent protected products intended to address mental health disorders affecting millions of people globally.”
While inviting drug development of its PsybraryTM collection of compounds by others with the potential of significant financial return, Enveric continues to focus on advancing its own lead programs, EB-002 and EB-003, to develop therapeutics for the treatment of specific mental health disorders and to maximize the impact of its investments.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, Psybrary™, Enveric has created a robust intellectual property portfolio of New Chemical Entities for specific mental health indications. Enveric’s lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders. Enveric is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include historical statements and statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: negotiate and finalize definitive agreements based on the three out-licensing term sheets and perform pursuant to the terms thereof; carry out successful clinical programs in
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311029002/en/
Investor Relations
Tiberend Strategic Advisors, Inc.
Daniel Kontoh-Boateng
(862) 213-1398
dboateng@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Source: Enveric Biosciences
FAQ
What patents did Enveric Biosciences (ENVB) recently secure?
What is the focus of Enveric's patents?
How do the patents benefit Enveric Biosciences (ENVB)?
Who is the Director and CEO of Enveric Biosciences?
What are Enveric's lead programs for mental health disorders?
